Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivospemin - Panbela Therapeutics

Next Previous
X
Search
Drug Profile

Ivospemin - Panbela Therapeutics

Alternative Names: [(HO)2-DEHSPM]; Diethyl dihydroxyhomospermine - Panbela Therapeutics; SBP-101; SUN 101

Latest Information Update: 02 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Florida
  • Developer Johns Hopkins University School of Medicine; Panbela Therapeutics
  • Class Antineoplastics; Polyamines; Small molecules
  • Mechanism of Action Adenosylmethionine decarboxylase inhibitors; Apoptosis stimulants; Caspase 3 stimulants; Cell division inhibitors; Ornithine decarboxylase inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pancreatic cancer
  • Preclinical Ovarian cancer

Most Recent Events

  • 31 Oct 2023 Panbela receives patent validation of European Patent in UK, Italy, Germany, France, and Spain for claims of a novel process for the production of Ivospemin
  • 26 Sep 2023 Panbela Therapeutics receives patent protection for method of production of Ivospemin in China
  • 14 Aug 2023 Panbela has patent protection for method of production of Ivospemin in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top